Research
Filter News
Found 142,651 articles
-
NYU Langone to Study Ability of Overdose Prevention Centers to Counter Unprecedented Overdose Crisis
5/8/2023
NYU Langone Health and Brown University's School of Public Health announced a grant award from the National Institute on Drug Abuse, part of the National Institutes of Health, to conduct research to measure the impact of some of the first publicly recognized overdose prevention centers in the United States, located in New York City and Providence, Rhode Island.
-
Telix to Supply Bayer with Illuccix® for Global Phase III Prostate Cancer Study
5/7/2023
Telix Pharmaceuticals Limited announces that it has entered into an agreement with Bayer AG to supply Illuccix® [1] for the Phase III ARASTEP study.
-
During a first-quarter earnings call, Novo revealed its hemophilia candidate had been blocked by the FDA, and that the company is reducing the U.S. supply of lower doses of weight-loss drug Wegovy. -
Idea Pharma’s annual index reveals key drivers and metrics for large companies. AstraZeneca and Pfizer remain in the top positions this year for invention and innovation, respectively. -
The companies said in first-quarter earnings calls that they want to restructure R&D, cut costs and shift away from high-risk drug development to focus areas. -
Research to Be Presented at ISPOR 2023 Illuminates the Economic Costs of Melanoma and Non-Small Cell Lung Cancer and Provides Insights That Can Help Strengthen the Quality and Approach to Real-World Evidence Generation
5/5/2023
Ontada®, a McKesson business dedicated to leveraging oncology real-world data, real-world evidence, clinical education, and provider technology to transform the fight against cancer, will be presenting research at ISPOR 2023, The Professional Society for Health Economics and Outcomes Research Annual Meeting taking place in Boston on May 7-10.
-
Feinstein Institutes’ 2023 Ross Prize awarded to fatty liver disease geneticists
5/5/2023
The Feinstein Institutes for Medical Research has selected two scientists from the University of Texas Southwestern Medical Center, Helen H. Hobbs, MD, and Jonathan C. Cohen, PhD, to receive the 10th annual Ross Prize in Molecular Medicine for groundbreaking research in dyslipidemias and metabolic liver disease.
-
Microbot Medical Announces Final Data From Its Recent Animal Study
5/5/2023
Microbot Medical Inc., the developer of the LIBERTY® Robotic System, the first single-use endovascular robotic system, has received the histopathology report from the European-based MedTech research laboratory that performed the animal study for the LIBERTY Robotic System in October 2022.
-
FibroGen Announces Results for MATTERHORN, a Phase 3 Clinical Study of Roxadustat for the Treatment of Anemia in Patients with Myelodysplastic Syndromes (MDS)Study Did Not Meet Primary Endpoint
5/5/2023
FibroGen, Inc. (NASDAQ: FGEN) today announced that MATTERHORN, a Phase 3 clinical study of roxadustat for treatment of anemia in patients with transfusion-dependent lower risk myelodysplastic syndromes (MDS) did not meet its primary efficacy endpoint.
-
Viva Biotech's Recent Conferences & Events Review
5/5/2023
In April, Viva Biotech was invited to attend 2022 SAPA-China Annual Conference, 88th API China, Drug Discovery Chemistry, American Association for Cancer Research (AACR) Annual Meeting 2023, CPHI Japan 2023, PharmFuture 2023 Small Molecule Innovative Drug Future Leadership Summit, 2023 China - Yangzhou Biopharmaceutical Forum, 2023 Dalian Biopharmaceutical Industry Conference and International Gene Festival, etc.
-
Aditxt Subsidiary Adimune Signs Clinical Trial Agreement with Top Research Institution to Study Stiff Person Syndrome
5/5/2023
Aditxt®, Inc. today announces that its subsidiary Adimune™, Inc. (“Adimune”), has signed a clinical trial agreement with Mayo Clinic to advance clinical studies targeting autoimmune diseases.
-
Seres Therapeutics to Host First Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on May 9, 2023
5/5/2023
Seres Therapeutics, Inc. today announced that management will host a conference call and live audio webcast on May 9, 2023 at 8:30 a.m. ET to discuss first quarter results and provide a general business update, including initial SER-155 Phase 1b safety and pharmacology results from study Cohort 1.
-
Visus Therapeutics Presents Topline Clinical Data from Phase 3 Pivotal BRIO-I Trial of BRIMOCHOL™ PF for the Treatment of Presbyopia at Eyecelerator @ ASCRS 2023
5/4/2023
Visus Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing multi-targeted ophthalmic therapies for indications in the front and back of the eye, today presented key topline data from the pivotal Phase 3 BRIO-I clinical trial.
-
NICO Awards $40,000 Grant to Study Genetic & Biological Make-Up of Meningioma Brain Tumors
5/4/2023
NICO Corporation, an Indianapolis-based pioneer and leader in minimally invasive neurosurgery, has awarded a $40,000 grant to Daniel Prevedello, MD, vice chair for Academic Affairs and director of Skull Base and Pituitary Surgery Programs at the Ohio State University Comprehensive Cancer Center.
-
Agilent Announces Solutions Innovation Research Award to Dr. Jiangbin Ye
5/4/2023
Agilent Technologies Inc. announced that Dr. Jiangbin Ye has received an Agilent Solutions Innovation Research Award.
-
Pieris Pharmaceuticals Announces Successful Completion of Safety Review for 10 mg Dose of Phase 2a Trial of Elarekibep (PRS-060/AZD1402)
5/4/2023
Pieris Pharmaceuticals, Inc. today announced the successful safety review of the 10 mg dry powder dose safety cohort from the ongoing multi-center, placebo-controlled phase 2a study of dry powder inhaler-formulated elarekibep (PRS-060/AZD1402).
-
LIfT BioSciences announces data demonstrating potent killing of pancreatic cancer tumouroids
5/4/2023
LIfT BioSciences today announces preclinical data demonstrating that its Immunomodulatory Alpha Neutrophil product (IMAN) showed potent killing of pancreatic cancer tumouroids.
-
Alphyn Biologics Reports Positive Pediatric Results from Phase 2a Atopic Dermatitis Trial
5/4/2023
Alphyn Biologics announced positive results today from the pediatric population enrolled in its Phase 2a clinical trial of AB-101a, a novel topical candidate for mild-to-moderate atopic dermatitis (AD), at the 22nd European Society for Pediatric Dermatology Congress (ESPD).
-
Soligenix Announces Positive Clinical Results from Compatibility Study of HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma
5/4/2023
Soligenix, Inc. announced today positive clinical results from a compatibility study evaluating HyBryte™ (synthetic hypericin sodium) in the treatment of cutaneous T-cell lymphoma (CTCL) using the commercially ready Daavlin Series 7 visible light device, which recently received 510(k) clearance from U.S. Food and Drug Administration (FDA).
-
Florida Cancer Specialists & Research Institute President & Managing Physician Lucio Gordan, MD Featured Speaker at Nationwide Oncology Event
5/4/2023
Florida Cancer Specialists & Research Institute, LLC President & Managing Physician Lucio Gordan, MD is among the national experts and physician leaders at the ION Exchange 2023 this week in San Diego who will share the latest clinical, operational and business insights to advance the quality of cancer care in community settings.